Arcutis and Sato announce strategic collaboration and licensing agreement for topical roflumilast in Japan

Arcutis Biotherapeutics, Inc. and Sato Pharmaceutical Co., Ltd., a leading pharmaceutical company, announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Japan.

Sato will receive an exclusive license for both the cream and foam formulations of topical roflumilast, a next generation phosphodiesterase type 4 (PDE4) inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, atopic dermatitis, and potentially additional dermatological conditions in the future.

Sato will be responsible for development, manufacturing, and commercialization of roflumilast cream and roflumilast foam and other topical roflumilast presentations in Japan. Arcutis will continue to be responsible for the development and commercialization of Zoryve (roflumilast) cream and Zoryve (roflumilast) foam in the United States and other geographies, excluding Greater China and Southeast Asia.